Syndax Pharmaceuticals Inc SNDX
We are a commercial-stage biopharmaceutical company advancing innovative cancer therapies. We currently have two commercially approved medicines, Revuforj® (revumenib) and Niktimvo (axatilimab-csfr), and a robust slate of clinical development programs designed to unlock the full potential of our first two products.
Revuforj is our first-in-class menin inhibitor that was approved by the U.S. Food and Drug Administration, or FDA, in November 2024 for the treatment of relapsed or refractory, or R/R, acute leukemia with a lysine methyltransferase 2A gene, or KMT2A, translocation in adult and pediatric patients one year old and older. In October 2025, Revuforj received a second approval from the FDA for the treatment of R/R acute myeloid leukemia, or AML, with a susceptible nucleophosmin 1 mutation, or NPM1m, in adult and pediatric patients one year and older who have no satisfactory alternative treatment options. We are also studying revumenib in combination with standard-of-care agents in NPM1m AML and KMT2A-rearranged, or KMT2Ar, acute leukemia across the treatment landscape, including in newly diagnosed patients. Additionally, we are exploring the potential for menin inhibition in the treatment of myelofibrosis, or MF.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $172.4M | $23.7M | $0 | $0 | $139.7M | $1.5M | $1.5M | $1.5M | $2.1M | $1.2M |
| R&D | $258.8M | $241.6M | $163.0M | $118.5M | $88.2M | $50.4M | $43.0M | $60.1M | $48.2M | $31.7M |
| SG&A | $179.7M | $120.9M | $66.9M | $33.3M | $25.2M | $22.5M | $16.1M | $17.3M | $15.9M | $13.3M |
| Total operating expenses | $445.4M | $363.4M | $230.0M | $151.8M | $113.5M | $72.9M | $59.1M | $77.4M | $64.1M | $45.0M |
| Operating income | -$273.1M | -$339.7M | -$230.0M | -$151.8M | $26.2M | -$71.4M | -$57.5M | -$75.9M | -$62.0M | -$43.8M |
| Interest expense | $6.0K | $1.0K | $208.0K | $3.1M | $1.9M | $2.4M | — | — | — | — |
| Pre-tax income | -$285.0M | — | — | — | $24.9M | -$73.2M | -$56.0M | -$74.0M | -$60.8M | -$44.5M |
| Income tax | $433.0K | — | — | — | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$285.4M | -$318.8M | -$209.4M | -$149.3M | $24.9M | -$73.2M | -$56.0M | -$74.0M | -$60.8M | -$44.5M |
| EPS, basic | -3.29 | -3.72 | -2.98 | -2.46 | 0.48 | -1.87 | -1.84 | — | — | — |
| EPS, diluted | -3.29 | -3.72 | -2.98 | -2.46 | 0.46 | -1.87 | -1.84 | -2.92 | -2.90 | -3.22 |
| Shares, diluted (wtd. avg.) | $86.6M | $85.6M | $70.4M | $60.8M | $53.6M | $41.3M | $30.5M | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $134.9M | $154.1M | $295.4M | $74.4M | $222.0M | $115.2M | $24.6M | $33.8M | $35.2M | $23.8M |
| Short-term investments | $259.1M | $418.8M | $275.3M | $401.4M | $218.0M | $177.8M | $35.2M | $47.1M | $94.8M | $81.5M |
| Receivables | $38.0M | $7.6M | $0 | — | — | — | — | — | — | — |
| Inventory | $32.8M | $366.0K | $0 | — | — | — | — | — | — | — |
| Total current assets | $528.1M | $603.1M | $580.9M | $489.8M | $448.4M | $298.9M | $62.3M | $83.3M | $133.4M | $108.5M |
| Property, plant and equipment | $181.0K | $0 | $8.0K | $20.0K | $278.0K | $192.0K | $281.0K | $373.0K | $267.0K | $260.0K |
| Total assets | $529.7M | $724.8M | $612.9M | $497.2M | $449.7M | $300.6M | $63.5M | $83.9M | $137.2M | $109.0M |
| Accounts payable | $16.6M | $11.6M | $10.0M | $4.3M | $5.7M | $3.5M | $6.2M | $1.4M | $2.2M | $2.4M |
| Short-term debt | $350.0M | $337.9M | $0 | — | — | — | — | — | — | — |
| Total current liabilities | $120.1M | $103.5M | $58.1M | $29.1M | $20.7M | $18.9M | $18.4M | $16.1M | $15.8M | $10.4M |
| Total liabilities | $465.1M | $436.7M | $58.7M | $29.8M | $41.3M | $48.4M | $31.9M | $30.9M | $32.9M | $24.9M |
| Retained earnings | -$1.51B | -$1.22B | -$902.4M | -$693.0M | -$543.7M | -$568.6M | -$495.5M | -$439.4M | -$366.1M | -$305.3M |
| Total equity | $64.6M | $288.1M | $554.2M | $467.4M | $408.4M | $252.2M | $31.6M | $53.0M | $104.3M | $84.1M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$323.0M | -$274.9M | -$160.6M | -$133.7M | $29.1M | -$71.3M | -$50.6M | -$68.5M | -$47.4M | -$35.2M |
| Depreciation and amortisation | $6.0M | $8.0M | $12.0M | $33.0M | $43.0M | $90.0K | $92.0K | $78.0K | $76.0K | $89.0K |
| Stock-based compensation | $47.5M | $43.0M | $31.0M | $16.0M | $13.3M | $9.1M | $6.0M | $6.2M | $5.5M | $4.7M |
| Capital expenditure | $187.0K | $0 | $0 | $0 | $129.0K | $0 | — | $187.0K | $84.0K | $261.0K |
| Investing cash flow | $290.0M | -$219.8M | $117.6M | -$186.2M | -$40.9M | -$142.5M | $12.8M | $51.4M | -$17.1M | -$18.3M |
| Financing cash flow | $13.7M | $353.4M | $264.1M | $172.3M | $118.5M | $304.4M | $28.6M | $15.7M | $75.7M | $54.2M |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-197859.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | $1.79T | — | — |
| LLY | ELI LILLY & Co | $1.08T | 50.1x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $663.28B | 25.0x | 6.0% |
| ONC | BeOne Medicines Ltd. | $529.55B | 1,885.6x | 40.2% |
| ABBV | AbbVie Inc. | $453.19B | 108.7x | 8.6% |
| MRK | Merck & Co., Inc. | $370.89B | 20.6x | 1.3% |
| ABT | ABBOTT LABORATORIES | $188.69B | 29.1x | 5.7% |
| PFE | PFIZER INC | $162.16B | 20.9x | -1.6% |